BioSpace News Archive

electroCore, a commercial-stage bioelectronic medicine company, will be presenting data from the PRESTO study evaluating gammaCore for the acute treatment of migraine.

Epigenomics AG announced promising results from two clinical studies published in EBioMedicine supported by Cell Press and The Lancet, demonstrating high accuracy of Epigenomics’ proprietary epigenetic circulating biomarker mSEPT9 in detecting liver cancer among patients with cirrhosis.

BONE THERAPEUTICS will announce its full year results for the year ended 31 December 2017 on Wednesday 25 April 2018 at 7am CEST.

Catalyst Pharmaceuticals, Inc. announced that the first patient has been enrolled into its Phase 3 clinical trial (designated as MSK-002) to evaluate the efficacy and safety of Firdapse® (amifampridine phosphate) in patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG).

Sodexo Canada and its public relations agency, Xposure PR, have been honored with a 2018 Gold Quill Award of Merit in Media Relations from the International Association of Business Communicators (IABC).

Varian (NYSE: VAR) today announced it has received FDA 510(k) clearance for its Calypso® Anchored Beacon® transponder.

TESARO, Inc. will announce first-quarter 2018 financial results onThursday, May 3, 2018, after the close of the U.S. financial markets.

Metabolon, Inc. announced that the U.S. Department of Veterans Affairs (VA) has been contracted through its alliance with AKESOgen, a leader in genomics, to perform large-scale metabolomic profiling on biological samples from U.S. veterans as part of the Million Veteran Program (MVP).

Mithra announces positive topline results from the E4 Relief Phase II study of Donesta® for the treatment of Vasomotor Symptoms (VMS), and in particular hot flushes relief, in post-menopausal women, with the study achieving its primary and key secondary objectives.

Polyphor announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its novel immuno-oncology candidate balixafortide (POL6326), in combination with eribulin, for the treatment of patients with HER2-negative metastatic breast cancer who previously received at least two chemotherapeutic regimens in the metastatic setting.